D酪氨酸激酶衰减蛋白2抗体简介说明

中文名称    D酪氨酸激酶衰减蛋白2抗体

英文名称    DOK2        

别    名    Docking protein 2 56kDa; Docking protein 2 antibody DOK 2; DOK R; Downstream of tyrosine kinase 2; p56(dok 2); p56dok 2; p56DOK; p56dok2; DOK2; DOK2_HUMAN; Downstream of tyrosine kinase 2; OTTHUMP00000161710; OTTHUMP00000224923; p56(dok 2); p56(dok-2).    

供应商      远慕生物

研究领域    肿瘤  细胞生物  信号转导  激酶和磷酸酶      

抗体来源    Rabbit    

克隆类型    Polyclonal    

交叉反应    Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit,     

产品应用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 D酪氨酸激酶衰减蛋白2抗体（石蜡切片需做抗原修复） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.    

分 子 量    45kDa    

性    状    Lyophilized or Liquid    

浓    度    1mg/1ml    

免 疫 原    KLH conjugated synthetic peptide derived from mouse DOK 2    

亚    型    IgG    

纯化方法    affinity purified by Protein A    

储 存 液    0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide    

保存条件    Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.    

D酪氨酸激酶衰减蛋白2抗体产品介绍    background:

The protein encoded by this gene is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210(bcr/abl), a chimeric protein whose presence is associated with CML. This encoded protein binds p120 (RasGAP) from CML cells. [provided by RefSeq, Jul 2008]

Function:
DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK2 may modulate the cellular proliferation induced by IL-4, as well as IL-2 and IL-3. May be involved in modulating Bcr-Abl signaling. Attenuates EGF-stimulated MAP kinase activation.